In a patient with diastolic dysfunction, ejection fraction 55%, impaired renal function, on torsemide 60 mg orally daily and who received intramuscular furosemide 40 mg with minimal response and has clear lungs but significant peripheral edema, what additional or alternative diuretics are recommended?

Diuretic Management for Refractory Edema in Heart Failure with Preserved Ejection Fraction

Add a thiazide-type diuretic (metolazone 2.5 mg once daily or hydrochlorothiazide 25-50 mg once or twice daily) to your current torsemide regimen to achieve sequential nephron blockade, which is the most effective strategy for overcoming diuretic resistance in your patient. 1

Rationale for Sequential Nephron Blockade

Your patient demonstrates classic diuretic resistance despite maximized loop diuretic therapy (torsemide 60 mg daily plus IM furosemide 40 mg). The combination of loop and thiazide diuretics creates synergistic effects by blocking sodium reabsorption at multiple sites along the nephron 1.

Specific Recommendations:

First-line addition:

• Metolazone 2.5 mg once daily is the preferred thiazide-type agent for sequential nephron blockade 1
• Can increase to 5-10 mg daily if inadequate response 1
• Administer 30-60 minutes before the loop diuretic dose for optimal effect 1

Alternative thiazide option:

• Hydrochlorothiazide 25-100 mg once or twice daily plus your current loop diuretic 1
• Note: Thiazides are generally less effective than metolazone when GFR <30 mL/min, though they work synergistically with loop diuretics even in reduced GFR 1

Optimizing Your Current Loop Diuretic Regimen

Before or concurrent with adding thiazide therapy, consider these adjustments:

Switch to twice-daily torsemide dosing:

• Your patient is on 60 mg once daily; consider splitting to 30-40 mg twice daily 1
• Twice-daily dosing is preferred over once-daily for patients with reduced GFR and nephrotic-range edema 1
• This maintains more consistent diuretic effect throughout the day and overcomes post-diuretic sodium retention 1

Consider IV loop diuretic administration:

• Oral bioavailability may be compromised by gut wall edema in volume-overloaded states 1
• IV torsemide or furosemide (bolus or continuous infusion) can overcome absorption issues 1
• Recent evidence shows no meaningful pharmacokinetic advantage of torsemide over furosemide; a 4:1 dose equivalence (furosemide:torsemide) produces similar natriuresis 2, 3, 4

Additional Diuretic Options

Aldosterone antagonist (if not already prescribed):

• Spironolactone 25-50 mg daily provides additional diuresis and counters hypokalemia from loop/thiazide combination 1
• Critical monitoring required: Check potassium and creatinine within 5-7 days given baseline creatinine 1.5-1.6 1
• Avoid if potassium >5.0 mEq/L or creatinine continues rising 1

Acetazolamide for enhanced decongestion:

• 500 mg IV once daily in addition to loop diuretics improves decongestion rates (42% vs 31% with placebo) 1
• Acts at proximal tubule to reduce compensatory sodium reabsorption 1
• Particularly useful for metabolic alkalosis from chronic loop diuretic use 1

Amiloride as alternative potassium-sparing agent:

• 5 mg once daily, can increase to 20 mg 1
• May improve diuresis while countering hypokalemia and metabolic alkalosis 1

Critical Monitoring Requirements

With combination diuretic therapy, monitor closely for:

• Electrolyte depletion: Risk markedly enhanced with two-diuretic combinations 1
• Renal function: Check creatinine and electrolytes within 5-7 days after adding thiazide, then every 5-7 days until stable 1
• Acceptable creatinine rise: Up to 30% increase is acceptable if signs of congestion are improving 1
• Stop diuretics if: Creatinine continues rising substantially without improvement in volume status, or if hyperkalemia develops (>5.0 mEq/L with aldosterone antagonist) 1

Important Caveats

Your patient's creatinine of 1.5-1.6 requires special consideration:

• This level warrants specialist referral per older guidelines (>150 μmol/L or ~1.7 mg/dL) 1
• However, aggressive diuresis is still appropriate with close monitoring 1
• The distinction between volume depletion versus worsening heart failure is critical: if peripheral edema persists with rising creatinine, this suggests worsening heart failure rather than over-diuresis 1

Avoid these common pitfalls:

• NSAIDs block diuretic effects and worsen renal function 1
• Excessive sodium intake (>2 g/day) antagonizes diuretic therapy 1
• Stopping ACE inhibitors/ARBs prematurely for modest creatinine rises (up to 30% acceptable) 1
• Using potassium supplements with aldosterone antagonists increases hyperkalemia risk 1

Recent evidence on torsemide versus furosemide:

• The TRANSFORM-HF trial showed no mortality or hospitalization benefit of torsemide over furosemide across all ejection fractions 3, 4
• Mechanistic studies demonstrate no pharmacokinetic advantage for torsemide; higher doses led to greater neurohormonal activation without improved volume status 2
• Your current torsemide 60 mg is roughly equivalent to furosemide 240 mg based on recent data showing 4:1 equivalence 2